Major challenges in providing an effective vaccine for H7N9 | CBRNE exercise preps Airmen for quick medical response | Study points to faster acting anthrax vaccine | FBI searches Spokane apartment in ricin letter case | Death toll rises to 36 in H7N9 outbreak | Neurotoxin: Mining the clostridium botulinum genome | DARPA awards 6M to develop nanotech therapies for brain injuries | Joint Task Force Civil Support to participate in readiness exercise | New methods for synthetic generation of influenza vaccines | Human infection with avian influenza H7N9 update | New malaria test kit gives a boost to elimination efforts worldwide | SAFETY Act program nears certification of 600 counterterrorism products | WHO experts nix yellow fever vaccine booster | Syrian chemical arms use seen in two cases, says State Department | Singapore’s first influenza vaccine in clinical testing | Evidence of host adaptation of avian-origin influenza A virus
See what we’re reading this week at Global Biodefense on topics like the SAFETY Act, botulinum genome research, yellow fever vaccine guidelines and more…
Major challenges in providing an effective vaccine for H7N9 (JAMA)
CBRNE exercise preps Airmen for quick medical response (US Air Force)
Study points to faster acting anthrax vaccine (NTI GSN)
FBI searches Spokane apartment in ricin letter case (Washington Post)
Death toll rises to 36 in H7N9 outbreak (CIDRAP)
Neurotoxin: Mining the clostridium botulinum genome (Science 2.0)
DARPA awards 6M to develop nanotech therapies for brain injuries (UCSD)
Joint Task Force Civil Support to participate in readiness exercise (CBRNe World)
New methods for synthetic generation of influenza vaccines (PRNewswire)
Human infection with avian influenza H7N9 update (WHO)
New malaria test kit gives a boost to elimination efforts worldwide (LAMP)
SAFETY Act program nears certification of 600 counterterrorism products (HSToday)
WHO experts nix yellow fever vaccine booster (CIDRAP)
Syrian chemical arms use seen in two cases, says State Department (NTI GSN)
Singapore’s first influenza vaccine in clinical testing (PRNewswire)
Evidence of host adaptation of avian-origin influenza A virus (Science China)
